La vendita allo scoperto per Perma-Pipe Inlt Hldgs dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Perma-Pipe Inlt Hldgs. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Perma-Pipe Inlt Hldgs (NASDAQ:PPIH) Azioni, Report sulle vendite allo scoperto

Perma-Pipe Inlt Hldgs

Perma-Pipe International Holdings Inc is engaged in the manufacture and sale of products in the reportable segment of Piping Systems. The company engineers, designs, manufactures and sells specialty piping systems and leak detection systems. Specialty piping systems include insulated and jacketed district heating and cooling piping systems for efficient energy distribution from central energy plants to multiple locations, primary and secondary containment piping systems for transporting chemicals, hazardous fluids and petroleum products, and the coating and insulation of oil and gas gathering and transmission pipelines. It operates in the United States, Canada, Middle East, Europe, India and other countries.

Perma-Pipe International Holdings, Inc. - Common Stock

Perma-Pipe International Holdings Inc

WIIM

Limbach Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.

<p>MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) affirms FY2024 Adj EPS guidance from $1.50-1.62 to $1.50-1.62 vs $1.49 analyst estimate..</p>


News

Guidance

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MasterBrand expects FY 2024 Net sales Y/Y increase of low single digits; Adj. EBITDA: $385M-$405M; Adj. Diluted EPS: $1.50-$1.62  VS Est. 1.49

RVLV

Revolve Group shares are trading higher after the company reported better-than-expected Q3 financial results.

<p>Northern Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.20 by 16.67 percent. This is a 19.08 percent decrease over earnings of $1.73 per share from the same period last year.  The company reported quarterly sales of $513.54 million which missed the analyst consensus estimate of $542.84 million by 5.40 percent.  This is a 0.37 percent increase over sales of $511.65 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

Northern Oil & Gas Q3 Adj $1.40 Beats $1.20 Estimate, Sales $513.54M Miss $542.84M Estimate

TMCI

Treace Medical Concepts shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance.

BBAI

BigBear.ai Affirms 2024 Revenue Guidance $165M-$180M

<p>BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent.  The company reported quarterly sales of $41.505 million which missed the analyst consensus estimate of $46.030 million by 9.83 percent.  This is a 22.12 percent increase over sales of $33.988 million the same period last year.</p>


BigBear.ai Hldgs Q3 2024 GAAP EPS $(0.05) Beats $(0.07) Estimate, Sales $41.505M Miss $46.030M Estimate

<p>Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.65 by 27.69 percent.  The company reported quarterly sales of $625.71 million which beat the analyst consensus estimate of $603.93 million by 3.61 percent.  This is a 63.10 percent increase over sales of $383.64 million the same period last year.</p>


GMED

Globus Medical Q3 2024 Adj EPS $0.83 Beats $0.65 Estimate, Sales $625.71M Beat $603.93M Estimate

B&G Foods shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 net sales guidance below estimates.

<p>Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction.</p>
<p>Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE&#x2122; (trofinetide) for the treatment of Rett syndrome. DAYBUE was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018. Pursuant to the license agreement, Acadia is required to pay Neuren one-third of the net proceeds.</p>
<p>Acadia plans to invest proceeds from the sale of the PRV to support its commercial operations, R&amp;D programs in central nervous system and rare disease, and future business development.</p>
<p>The transaction is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Jefferies LLC acted as financial advisor to Acadia on this transaction.</p>


Asset Sales

ACAD

Acadia Pharmaceuticals Enters Into An Agreement To Sell Its Rare Pediatric Disease Priority Review Voucher For $150M

<p>Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) reported quarterly earnings of $0.14 per share.  The company reported quarterly sales of $37.640 million which missed the analyst consensus estimate of $42.000 million by 10.38 percent.  This is a 649.35 percent increase over sales of $5.023 million the same period last year.</p>


GIFI

Gulf Island Fabrication Q3 2024 GAAP EPS $0.14, Sales $37.640M Miss $42.000M Estimate

Ternium Q3 2024 EPADS $0.16, Sales $4.480B Beat $4.446B Estimate

<p><i>New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC</i></p>
<p><i>Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH</i></p>
<p>SAN DIEGO, Nov. 5, 2024 /PRNewswire/ --&nbsp;Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced new preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) 39th&nbsp;Annual Meeting in Houston, November 6-10.</p>


Biotech

General

PSTX

Poseida Therapeutics To Present Clinical And Preclinical Data On Investigational Allogeneic CAR-T Cell Therapies At SITC 2024 And ASH 2024

QLYS

Qualys Expects Q4 Adj EPS Of $1.28 - $1.38 (Est $1.28), Revenues Of $154.5M - $157.5M (Est $154.059M)

MGNX

MacroGenics shares are trading higher after the company reported better-than-expected Q3 financial results.

International Flavors & Fragrances Sees FY24 Sales $11.3B-$11.4B Vs $11.288B Est.

<p>–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <i>Real World Study Compared Over 150,000 Adult &amp; Pediatric Patients –</i><br /><br />–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <i>Caldolor Associated with Fewer Adverse Drug Reactions –</i><br /><br />–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <i>Caldolor also Improved Healthcare Utilization –</i></p>
<p>NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (<i>ibuprofen</i>) injection over ketorolac in both adult and pediatric populations. The study, published in <i>Frontiers of Pain Research</i>, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations when compared to ketorolac.</p>
<p>This extensive, retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or Caldolor. Ultimately, 31,046 Caldolor and 124,184 ketorolac adult patients were selected and compared for ADRs and subsequent healthcare resource utilization, which includes inpatient, outpatient and emergency department visits as well as all procedures and prescriptions during the follow up time of 29 days. An additional 5,579 pediatric patients were identified in each arm and compared in a separate claims analysis.</p>
<p>Key findings reveal that, in adults, Caldolor was associated with a 45% reduction in renal dysfunction (p&lt;0.001) and a 78% decrease in hematuria rates (p&lt;0.001) when compared to ketorolac. Notably, patients also experienced fewer gastrointestinal complications as well as reduced headaches, nausea and abdominal pain. Among pediatric patients, the results showed Caldolor was associated with a 51-65% lower rate of ADRs, including headache and nausea, with 95% confidence intervals supporting clinical significance.</p>
<p>Caldolor also demonstrated a positive impact on healthcare resource utilization (HCRU) when compared to ketorolac, with decreased emergency room and outpatient visits, as well as a shortened hospital length of stay for both adults and children.</p>


CPIX

Cumberland Pharmaceuticals Announces The Publication Of New Real-World Outcomes Research Demonstrating The Safety And Healthcare Resource Advantages Of Its Caldolor (Ibuprofen) Injection Over Ketorolac In Both Adult And Pediatric Populations

AVNW

Aviat Networks shares are trading lower after the company reported worse-than-expected Q1 financial results and lowered its FY25 sales guidance.

<p>Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) affirms FY2024 Adj EPS guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 analyst estimate. Affirms FY2024 sales outlook from $425.00 million-435.00 million to $425.00 million-435.00 million vs $430.33 million estimate.</p>


FORR

Forrester Res Affirms FY2024 Adj EPS Guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 Est; Affirms FY2024 Sales Guidance from $425.00M-435.00M to $425.00M-435.00M vs $430.33M Est.

<p>Sixth Street Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) reported quarterly earnings of $0.57 per share which met the analyst consensus estimate. This is a 5 percent decrease over earnings of $0.60 per share from the same period last year.  The company reported quarterly sales of $119.223 million which beat the analyst consensus estimate of $118.508 million by 0.60 percent.  This is a 4.18 percent increase over sales of $114.435 million the same period last year.</p>


TSLX

Sixth Street Specialty Q3 2024 Adj. EPS $0.57, Inline, Sales $119.223M Beat $118.508M Estimate

The market has been high on Perma-Pipe International Holdings Inc (PPIH)  stock recently. PPIH gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Perma-Pipe International Holdings Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PPIH!See Full PPIH

Is Perma-Pipe International Holdings Inc (PPIH) Stock About to Get Hot Friday?

View, VerifyMe, Smith & Wesson Brands among industrial movers

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Perma-Pipe Inlt Hldgs</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ppih-stock-quote/"><strong>PPIH</strong></a></span>) just reported results for the third quarter of 2023.</p><ul><li>Perma-Pipe Inlt Hldgs reported earnings per share of 24 cents.</li><li>The company reported revenue of $45.69 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2023/12/ppih-stock-earnings-perma-pipe-inlt-hldgs-for-q3-of-2023/">PPIH Stock Earnings: Perma-Pipe Inlt Hldgs Reported Results for Q3 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

PPIH Stock Earnings: Perma-Pipe Inlt Hldgs Reported Results for Q3 2023

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Perma-Pipe Inlt Hldgs</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ppih-stock-quote/"><strong>PPIH</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Perma-Pipe Inlt Hldgs reported earnings per share of $1.08.</li><li>The company reported revenue of $40.18 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/ppih-stock-earnings-perma-pipe-inlt-hldgs-for-q4-of-2023/">PPIH Stock Earnings: Perma-Pipe Inlt Hldgs Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

PPIH Stock Earnings: Perma-Pipe Inlt Hldgs Reported Results for Q4 2023

Perma-Pipe International GAAP EPS of $1.08, revenue of $40.2M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Perma-Pipe Inlt Hldgs</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ppih-stock-quote/"><strong>PPIH</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Perma-Pipe Inlt Hldgs reported earnings per share of 18 cents.</li><li>The company reported revenue of $34.32 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/06/ppih-stock-earnings-perma-pipe-inlt-hldgs-for-q1-of-2024/">PPIH Stock Earnings: Perma-Pipe Inlt Hldgs Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

PPIH Stock Earnings: Perma-Pipe Inlt Hldgs Reported Results for Q1 2024

Perma-Pipe announces $10M in contract awards in Saudi Arabia

VP Harris pledges not to ban fracking; Trump would slash Biden clean power plans

Perma-Pipe International GAAP EPS of $0.40, revenue of $37.5M

BOIL

DRIP

EOSE

GUSH

HNRG

IMPP

KOLD

NFGC

PPIH

SATL

SBSW

SPIR

USOI

VIEW

Press Releases

Perma-Pipe International Holdings, Inc. Announces its Third Quarter Fiscal 2023 Financial Results

Perma-Pipe International Holdings announces acceptance into QatarEnergy's Tawteen Program

Perma-Pipe International Holdings, Inc. Announces Fourth Quarter and Fiscal 2023 Financial Results

Perma-Pipe International Holdings, Inc. Announces First Quarter Fiscal 2024 Financial Results

Perma-Pipe International Holdings, Inc. Announces $10 Million in Contract Awards in Saudi Arabia

Perma-Pipe International Holdings, Inc., announces $46 million in Contract Awards in the Middle East Region

Perma-Pipe International Holdings, Inc. Announces Second Quarter Financial Results

Perma-Pipe International Holdings, Inc., announces $4 million in Contract Awards in the Americas Region

Comments

Perma-Pipe Inlt Hldgs

Vendite allo scoperto

Perma-Pipe Inlt Hldgs (NASDAQ:PPIH) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO